DL-4-methoxy-phenyl-alanine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-4-methoxy-phenyl-alanine
• 英文别名: N-(4-methoxyphenyl)alanine；(2S)-2-(4-methoxyanilino)propanoic acid
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: NBIAPSSMDVYOQH-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  甲醇 、 DL-4-methoxy-phenyl-alanine 在 氯化亚砜 作用下， 以44.4 %的产率得到(S)-methyl 2-((4-methoxyphenyl)amino)propanoate
  参考文献：
  名称：

  CN116785449

  摘要：

  公开号：
• 作为产物：
  描述：

  L-丙氨酸 、 4-碘苯甲醚 在 copper(I) oxide 、 potassium phosphate 作用下， 以 N-甲基吡咯烷酮 为溶剂， 以51.2 %的产率得到DL-4-methoxy-phenyl-alanine
  参考文献：
  名称：

  CN116785449

  摘要：

  公开号：

文献信息

• 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
  申请人：Binet Jean

  公开号：US20060025589A1

  公开（公告）日：2006-02-02

  The invention relates to 2-thiohydantoin compounds selected from compounds of general formula (I): in which, in particular, one of the radicals R 1 and R 2 comprises two aromatic rings in the structure or is the dibenzofuranyl group, R 3 is a hydrogen atom, a halogen atom, a C 1 -C 4 alkyl group, a C 1 -C 4 alkoxy group, a hydroxyl group, a phenyl group or a benzyl group, R 4 is a hydrogen atom, a halogen atom or a C 1 -C 4 alkyl group, and their addition salts with a non-toxic acid, especially the pharmaceutically acceptable salts. It further relates to the process for their preparation, to the pharmaceutical compositions in which they are present, and to their use as pharmacologically active substances, especially in the case of the treatment of diabetes, diseases due to hyperglycemia, hypertriglyceridemia, dyslipidemia or obesity.

  本发明涉及通式(I)化合物中选自2-硫代海因的化合物：其中，特别是其中一个取代基R1和R2包含两个芳香环结构或为二苯并呋喃基团，R3为氢原子、卤素原子、C1-C4烷基团、C1-C4烷氧基团、羟基团、苯基团或苄基团，R4为氢原子、卤素原子或C1-C4烷基团，以及它们与非毒性酸的加成盐，特别是药学上可接受的盐。本发明还涉及它们的制备方法、含有它们的药物组合物，以及它们作为药理活性物质，特别是在治疗糖尿病、高血糖引起的疾病、高甘油三酯血症、血脂异常或肥胖症中的应用。
• [EN] OPTICAL PROBE FOR THROMBIN<br/>[FR] SONDE OPTIQUE POUR THROMBINE
  申请人：UNIV COURT UNIV OF EDINBURGH

  公开号：WO2016151297A1

  公开（公告）日：2016-09-29

  Optical probes are presented, the probes comprising a first probe element, and a second probe element connected to a core. The first probe element comprises a first fluorophore connected to a first quencher by a first cleavable linker. The second probe element comprises a second fluorophore connected to a second quencher by a second cleavable linker. The first fluorophore is separated from the first quencher when the first cleavable linker is cleaved, and the second fluorophore is separated from the second quencher when the second cleavable linker is cleaved. Methods of detecting a first and second enzyme using the optical probe are also presented.

  光学探针包括第一探针元件和连接到核心的第二探针元件。第一探针元件包括第一荧光素通过第一可切割连接剂连接到第一猝灭剂。第二探针元件包括第二荧光素通过第二可切割连接剂连接到第二猝灭剂。当第一可切割连接剂被切割时，第一荧光素与第一猝灭剂分离，当第二可切割连接剂被切割时，第二荧光素与第二猝灭剂分离。还提供了使用光学探针检测第一和第二酶的方法。
• [EN] 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE ET DE 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D'ORÉXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2013068935A1

  公开（公告）日：2013-05-16

  The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2- yl)picolinamide derivatives of formula (I) Formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式(I)的2-(1,2,3-三唑-2-基)苯甲酰胺和3-(1,2,3-三唑-2-基)吡啶甲酰胺衍生物，式(I)中Ar1、Q以及R1至R5如描述，它们的制备方法，它们的药用盐，以及它们作为药物的用途，含有式(I)的一个或多个化合物的药物组合物，特别是它们作为促进睡眠的受体拮抗剂的用途。
• 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150158855A1

  公开（公告）日：2015-06-11

  The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I) wherein Ar 1 , Q, and R 1 to R 5 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）中的2-(1,2,3-三唑-2-基)苯甲酰胺和3-(1,2,3-三唑-2-基)吡啶甲酰胺衍生物，其中Ar1、Q和R1至R5如描述所述，以及它们的制备方法，其药学上可接受的盐，以及它们作为药物的用途，含有一个或多个公式（I）化合物的药物组合物，特别是它们作为促进睡眠激素受体拮抗剂的用途。
• Thiohydantoins and use thereof for treating diabetes
  申请人：——

  公开号：US20040116417A1

  公开（公告）日：2004-06-17

  The invention relates to 2-thiohydantoin derivative compounds selected from compounds of general formula (I): 1 as defined in the claims, and to their addition salts with an acid, notably pharmaceutically acceptable salts. The invention also relates to their method of preparation, the pharmaceutical compositions containing them, and their use as pharmacologically active substance, notably in the case of the treatment of diabetes and diseases caused by a hyperglycaemia, hypertriglyceridaemiae, dyslipidaemiae or obesity.

  本发明涉及从一般式(I)所述的化合物中选择的2-硫代异恶唑衍生物化合物，以及它们与酸形成的加合物盐，尤其是药学上可接受的盐。本发明还涉及它们的制备方法，含有它们的药物组合物，以及它们作为药理活性物质的用途，尤其是在治疗糖尿病以及由高血糖、高三酰甘油血症、血脂异常或肥胖引起的疾病的情况下。